Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0000882095
$157.19
+2.36% · live
Updated
$195.07B market value
From GILEAD SCIENCES, INC.'s FY2025 10-K, filed Feb 24, 2026 · read the filing
GILEAD SCIENCES develops and makes medicines. It took in $29.44B last year, which makes it a large company. Of every dollar it sells, about 29 cents is left as profit.
The financial picture is led by profitability, debt and accounting, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From GILEAD SCIENCES, INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$1.66B → $10.02B
Profit
$480.0M → $8.51B
Operating margin
5.8% → 34.0%
Profit margin
1.7% → 28.9%
Measured against FY2024, from the 10-K filed Feb 24, 2026
Improved: +503.0%
$1.66B to $10.02BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +1672.9%
$480.0M to $8.51BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
GILD rose 2.36% on the latest quote. The average Health Care company tracked here moved +1.60%, and the S&P 500 −1.04%. That is 0.8 points above its sector and 3.4 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 7% a year for the next 10 years. Over the last 10 years it shrank by about 7% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 29 cents of every dollar of sales as profit, earning $8.51B last year.
Barely. Sales were roughly flat, up 2.4%.
No. At its current cash flow it could clear its debt in about 1.7 years. For every $1 it owes, it owns $1.63 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 47 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 40% of the cash its operations generated. It has paid in each of the last 11 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $8.51B and generated $10.02B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 24, 2026Filing for FY2025 | FY202410-K · Feb 28, 2025Filing for FY2024 | FY202310-K · Feb 23, 2024Filing for FY2023 | FY202210-K · Feb 22, 2023Filing for FY2022 | FY202110-K · Feb 23, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B | +2.4% |
| Cost of revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | −0.3% |
| Gross profit | $23.21B† | $22.50B† | $20.62B† | $21.62B† | $20.70B† | +3.1% |
| Gross marginGross profit ÷ revenueWhat is this? | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | +0.6 pts |
| Selling, general and administrative | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | −5.2% |
| Operating income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | +503.0% |
| Operating marginOperating income ÷ revenueWhat is this? | 34.0% | 5.8% | 28.0% | 26.9% | 36.3% | +28.3 pts |
| Interest expense | $1.02B | $977.0M | $944.0M | $935.0M | $1.00B | +4.8% |
| Income before tax | $9.80B | $690.0M | $6.86B | $5.81B | $8.28B | +1319.7% |
| Net income | $8.51B | $480.0M | $5.67B | $4.59B | $6.22B | +1672.9% |
| Net marginNet income ÷ revenueWhat is this? | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | +27.2 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $6.86 | $0.3852 | $4.55 | $3.68 | $4.96 | +1680.1% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| GILDGILEAD SCIENCES, INC. · this page | 9.0/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 3,000 shares at $156.22 ($468.7K)
Holds 113,684 shares after this filing.
Sold on the open market
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Quarterly report for Q2 FY2026
Revenue +10.2% · Operating margin −168.1 pts · Operating income turned negative — against Q2 FY2025
Read the filingPublished results
Read the filingWrite down why you are following GILEAD SCIENCES, INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 84 subsidiaries named in its 10-K, incorporated across 42 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from GILD's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 24, 2026), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 9.0 | 8/9 | 10-K, filed Feb 24, 2026 |
| FY2024 | 6.0 | 7/9 | 10-K, filed Feb 28, 2025 |
| FY2023 | 8.0 | 7/9 | 10-K, filed Feb 23, 2024 |
| FY2022 | 8.0 | 8/9 | 10-K, filed Feb 22, 2023 |
| FY2021 | 9.0 | 7/9 | 10-K, filed Feb 23, 2022 |
| FY2020 | 6.0 | 5/9 | 10-K, filed Feb 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
4.74
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.45
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +28.3 pts
5.8% to 34.0%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +27.2 pts
1.7% to 28.9%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +1680.1%
$0.39 to $6.86Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -24.3%
$9.99B to $7.56BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: -8.2%
$10.30B to $9.46BNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: -11.1%
$24.90B to $22.13BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Changed: +7.6%
$523.0M to $563.0MNotable
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 6, 2026 — read it.
Deteriorated: turned negative
$2.47B to -$10.39BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: turned negative
$1.96B to -$10.50BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −168.1 pts
34.9% to -133.2%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −162.2 pts
27.7% to -134.5%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$1.58 to -$8.46Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -38.2%
$5.14B to $3.18BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +10.2%
$7.08B to $7.80BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +11.5%
$5.58B to $6.22BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: +7.6%
$22.14B to $23.83BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 6, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Deteriorated: turned negative
$2.59B to -$10.39BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: turned negative
$2.02B to -$10.50BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Deteriorated: −170.4 pts
37.2% to -133.2%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −163.5 pts
29.0% to -134.5%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Deteriorated: turned negative
$1.63 to -$8.46Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: -58.3%
$7.63B to $3.18BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +12.1%
$6.96B to $7.80BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +12.9%
$5.51B to $6.22BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: +14.2%
$20.86B to $23.83BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
5 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 5% and 9%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 37 analysts covering this company, as of . Their views, not this site's.
Of 37 analysts publishing on this company, 9 say strong buy, 21 say buy and 7 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Trailing P/E is not meaningful because the latest trailing earnings are zero or negative. The price-to-book and price-to-sales figures below still provide reference points.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| 2.4% |
| 28.9% |
| 22.92x |
| 1.60x |
| ABBVAbbVie Inc. | 7.0/10 | 8/9 | 8.6% | 6.9% | 119.13x | -41.97x |
|---|
| AMGNAMGEN INC | 8.0/10 | 8/9 | 10.0% | 21.0% | 31.25x | 9.46x |
|---|
| VRTXVERTEX PHARMACEUTICALS INC / MA | 8.7/10 | 6/8 | 8.9% | 32.9% | 34.38x | 0.37x |
|---|
| REGNREGENERON PHARMACEUTICALS, INC. | 8.7/10 | 6/8 | 1.0% | 31.4% | 19.02x | 0.30x |
|---|
| MRNAModerna, Inc. | 6.0/10 | 3/9 | -39.9% | -145.2% | — | 0.43x |
|---|
| Median of peers | 8.0/10 | — | 8.6% | 21.0% | 32.82x | 0.37x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Holds 161,096 shares after this filing.
Sold on the open market — 12,000 shares at $147.72 ($1.8M)
Holds 569,683 shares after this filing.
Sold on the open market — 3,000 shares at $148.63 ($445.9K)
Holds 566,683 shares after this filing.
Exercised stock options — 2,223 shares
Holds 2,223 shares after this filing.
Had shares withheld to cover taxes — 768 shares at $152.67 ($117.3K)
Holds 1,455 shares after this filing.
Sold on the open market — 1,600 shares at $143.69 ($229.9K)
Holds 118,084 shares after this filing.
Sold on the open market — 800 shares at $144.46 ($115.6K)
Holds 117,284 shares after this filing.
Sold on the open market — 600 shares at $145.29 ($87.2K)
Holds 116,684 shares after this filing.
Sold on the open market — 3,000 shares at $145.29 ($435.9K)
Holds 164,096 shares after this filing.
Exercised stock options — 533 shares
Holds 19,785 shares after this filing.
Had shares withheld to cover taxes — 263 shares at $144.81 ($38.1K)
Holds 19,522 shares after this filing.
Exercised stock options — 2,797 shares
Holds 168,443 shares after this filing.
Had shares withheld to cover taxes — 1,347 shares at $144.81 ($195.1K)
Holds 167,096 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 3,000 shares ($468.7K) on or after .
Shares originally obtained via Performance Shares.
Filed notice to sell 3,000 shares ($468.7K) on or after .
Shares originally obtained via Performance Shares.
Filed notice to sell 3,000 shares ($435.9K) on or after .
Shares originally obtained via Performance Shares.
Filed notice to sell 3,000 shares ($432.6K) on or after .
Shares originally obtained via Performance Shares.
Filed notice to sell 18,000 shares ($2.7M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 5,000 shares ($738.0K) on or after .
Shares originally obtained via Exercise of Stock Options.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Signed a material agreement · Took on a direct financial obligation · Reported another event
Quarterly report for Q1 FY2026
Operating margin +3.6 pts · Profit +53.7% · Profit margin +9.3 pts — against Q1 FY2025
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingMade a Regulation FD disclosure · Reported another event
Read the filingProxy statement for a shareholder meeting
Read the filingAnnual report for FY2025
Operating margin +28.3 pts · Operating income +503.0% · Profit +1672.9% — against FY2024
Read the filingSigned a material agreement · Made a Regulation FD disclosure
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q3 FY2025
Operating margin +31.1 pts · Operating income +274.7% · Profit +143.6% — against Q3 FY2024
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join
Read the filingQuarterly report for Q2 FY2025
Operating margin −3.1 pts · Cash +85.6% · Profit +21.4% — against Q2 FY2024
Read the filingPublished results
Read the filingAmended its charter or changed its financial year
Read the filingHeld a shareholder vote
Read the filingThe first 40 of 84. The rest are in the exhibit.
Source: Exhibit 21 of the 10-K filed 2026-02-24. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?
Yahoo ·
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Yahoo ·
Sector Update: Healthcare Stocks Gain Late Afternoon
Yahoo ·
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Yahoo ·
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Yahoo ·
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
Yahoo ·
BioNTech Enters Clinical Trial Collaboration And Supply Agreement With Gilead Sciences To Evaluate Pumitamig In Combination With Sacituzumab Govitecan As First-Line Treatment For Patients With Locally Advanced Or Metastatic PD-L1 Low Or Negative Triple-negative Breast Cancer
Benzinga ·
Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note
Yahoo ·
Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
SeekingAlpha ·
Occidental Petroleum To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga ·
B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $172
Benzinga ·
How Investors Are Reacting To Gilead Sciences (GILD) FDA Drug Approvals
Yahoo ·
Primary sources and further research